Symptoms of overdose include erythema, stinging, blistering, peeling, edema, pruritus, urticaria, burning, and general irritation of the skin, and cramps. As with all topical agents, skin sensitization may result F3088.
Oral LD50 (rat): 708 mg/kg; Intraperitoneal LD50 (rat): 445 mg/kg; Subcutaneous LDLO (rat): 10 g/kg; Oral LD50 (mouse): 761 mg/kg; Subcutaneous LDLO (mouse): 10 g/kg; Intraperitoneal LD50 (mouse): 108 mg/kg;F3124
Overdose
This drug poses no risk of acute intoxication, as it is unlikely to occur following a single vaginal or dermal application of an overdose (application over a large area under conditions favorable to absorption) or accidental oral ingestion. There is no specific antidote F3100.
Effects on Fertility
No human studies of the effects of clotrimazole on fertility have been conducted; however, animal studies have not shown any effects on the drug on fertility F3088.
Use in Pregnancy
There are limited data regarding the use of clotrimazole in pregnant women. Animal studies do not show direct or indirect harmful effects on reproduction. Although the topical application of clotrimazole may result in very low serum and tissue levels, the use of clotrimazole topical cream by pregnant women is not recommended unless it is advised by the prescribing physician. Clotrimazole topical cream should not be used in the first trimester of pregnancy unless it is considered by the physician to be essential to patient well-being F3088.
Use in Breastfeeding
Available pharmacodynamic/toxicological studies in animals have shown excretion of clotrimazole/metabolites in breastmilk. Clotrimazole should not be administered during breastfeeding. Although the topical application of clotrimazole has resulted in very low serum and tissue levels, the use of clotrimazole topical cream by lactating women is not recommended unless it recommended by the prescribing physician F3088.
This drug is a broad spectrum antimycotic or antifungal agent. Clotrimazole's antimycotic properties were discovered in the late 1960s A174094. Clotrimazole falls under the imidazole category of azole antifungals, possessing broad-spectrum antimycotic activity A174094. It is available in various preparations, including creams, pessaries, and troche formulations (slowly dissolving tablets). As well as its antifungal activity, clotrimazole has become a drug of interest in treating several other diseases such as sickle cell disease, malaria and some cancers A174094. The minimal side effect profile of this drug and its uncomplicated metabolic profile have led it to gain widespread acceptance for the treatment of mycotic outbreaks such as vaginal yeast infections as well as athlete's foot A174097.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Tacrolimus | The serum concentration of Tacrolimus can be increased when it is combined with Clotrimazole. |
| Sirolimus | The serum concentration of Sirolimus can be increased when it is combined with Clotrimazole. |
| Dicoumarol | The therapeutic efficacy of Dicoumarol can be increased when used in combination with Clotrimazole. |
| Phenindione | The therapeutic efficacy of Phenindione can be increased when used in combination with Clotrimazole. |
| Phenprocoumon | The therapeutic efficacy of Phenprocoumon can be increased when used in combination with Clotrimazole. |
| 4-hydroxycoumarin | The therapeutic efficacy of 4-hydroxycoumarin can be increased when used in combination with Clotrimazole. |
| Coumarin | The therapeutic efficacy of Coumarin can be increased when used in combination with Clotrimazole. |
| Ethyl biscoumacetate | The therapeutic efficacy of Ethyl biscoumacetate can be increased when used in combination with Clotrimazole. |
| Fluindione | The therapeutic efficacy of Fluindione can be increased when used in combination with Clotrimazole. |
| Clorindione | The therapeutic efficacy of Clorindione can be increased when used in combination with Clotrimazole. |
| Diphenadione | The therapeutic efficacy of Diphenadione can be increased when used in combination with Clotrimazole. |
| Tioclomarol | The therapeutic efficacy of Tioclomarol can be increased when used in combination with Clotrimazole. |
| Warfarin | The therapeutic efficacy of Warfarin can be increased when used in combination with Clotrimazole. |
| Acenocoumarol | The therapeutic efficacy of Acenocoumarol can be increased when used in combination with Clotrimazole. |
| (R)-warfarin | The therapeutic efficacy of (R)-warfarin can be increased when used in combination with Clotrimazole. |
| (S)-Warfarin | The therapeutic efficacy of (S)-Warfarin can be increased when used in combination with Clotrimazole. |
| Lemborexant | The serum concentration of Lemborexant can be decreased when it is combined with Clotrimazole. |
| Clindamycin | The metabolism of Clindamycin can be increased when combined with Clotrimazole. |
| Rimegepant | The metabolism of Rimegepant can be increased when combined with Clotrimazole. |
| Capmatinib | The serum concentration of Capmatinib can be decreased when it is combined with Clotrimazole. |
| Selpercatinib | The serum concentration of Selpercatinib can be decreased when it is combined with Clotrimazole. |
| Rilpivirine | The serum concentration of Rilpivirine can be decreased when it is combined with Clotrimazole. |